• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of pharmacy technology: jPT : official publication of the Association of Pharmacy Technicians >Effect of Obesity on Clinical Outcomes of Patients Treated With Cefepime
【24h】

Effect of Obesity on Clinical Outcomes of Patients Treated With Cefepime

机译：肥胖对头脑治疗患者临床结果的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: As the prevalence of obesity climbs, dosing of antimicrobials, particularly cephalosporins, is becoming a greater challenge for clinicians. Data are lacking for appropriate dosing of cefepime, an anti-pseudomonal cephalosporin that is widely used as an empiric anti-pseudomonal agent. Objective: The purpose of this study was to determine the rate of clinical treatment failure in obese patients compared with nonobese patients receiving cefepime as definitive monotherapy. Methods: Adult inpatients treated with cefepime monotherapy for ≥72 hours were included. Patients were excluded if they (1) were not able to achieve culture clearance within 72 hours and (2) had polymicrobial infections requiring more than one antibiotic for definitive therapy. Results: Fifty-eight obese patients and 56 nonobese patients were included. Pseudomonas aeruginosa , Escherichia coli , and Enterobacter spp were the most prevalent organisms isolated. Most organisms had a minimum inhibitory concentration of ≤1 μg/mL to cefepime with no differences in minimum inhibitory concentration distributions between groups. Definitively, 60% of patients received cefepime 1 g, while almost 40% received cefepime 2 g. Clinical failure occurred in 52% of patients (67% obese vs 36% nonobese; P = .001), with study group (odds ratio = 1.057, 95% confidence interval = 1.008-1.109) and respiratory source (odds ratio = 3.251, 95% confidence interval = 1.378-7.667) being independent predictors of failure. There were no differences in hospital length of stay, all-cause mortality, or 30-day readmissions. Conclusions: Obese patients treated with cefepime are more likely to experience treatment failure than nonobese patients. Larger trials examining the reasons for clinical failure in obese patients treated with cefepime are needed to confirm the findings from this preliminary work.
机译：背景：随着肥胖率的攀升，抗生素，尤其是头孢菌素的剂量正在成为临床医生面临的更大挑战。头孢吡肟是一种被广泛用作经验性抗假单胞菌药物的抗假单胞菌头孢菌素，目前尚无适当剂量的数据。目的：本研究的目的是确定肥胖患者与接受头孢吡肟作为最终单一疗法的非肥胖患者的临床治疗失败率。方法：对成人住院患者采用头孢吡肟单药治疗≥包括72小时。如果患者（1）无法在72小时内实现培养清除，并且（2）患有需要一种以上抗生素进行最终治疗的多微生物感染，则将其排除在外。结果：58例肥胖患者和56例非肥胖患者被纳入研究。铜绿假单胞菌、大肠杆菌和肠杆菌是最常见的分离菌。大多数生物体的最低抑制浓度为≤头孢吡肟1μg/mL，组间最小抑菌浓度分布无差异。确切地说，60%的患者服用头孢吡肟1g，而近40%的患者服用头孢吡肟2g。52%的患者出现临床失败（67%肥胖患者与36%非肥胖患者；P=0.001），研究组（优势比=1.057，95%可信区间=1.008-1.109）和呼吸源（优势比=3.251，95%可信区间=1.378-7.667）是失败的独立预测因素。住院时间、全因死亡率或30天再入院率没有差异。结论：与非肥胖患者相比，接受头孢吡肟治疗的肥胖患者更有可能经历治疗失败。为了证实这项初步研究的发现，需要对使用头孢吡肟治疗的肥胖患者的临床失败原因进行更大规模的试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号